Department of Pharmaceutical Sciences, School of Pharmacy, Lebanese International University, Beirut, Lebanon.
Pharmaceutical Nanotechnology Research Lab, Faculty of Pharmacy, Beirut Arab University, Beirut, Lebanon.
Int J Nanomedicine. 2024 Nov 9;19:11561-11576. doi: 10.2147/IJN.S469570. eCollection 2024.
Cancer ranks as the second most common cause of mortality as depicted by the World Health Organization, with one in six deaths being cancer-related mortality. Taking the lead in females, breast cancer is the most common neoplasm. Raloxifene, a selective estrogen receptor modulator, has been utilized as a chemotherapeutic agent for the treatment of breast cancer in postmenopausal women. However, its poor aqueous solubility hinders its clinical applications. Beta-cyclodextrin-based framework is a novel class of nano-vectors that used to potentiate the solubility and dissolution rate of poorly soluble drugs.
The present study investigates the solubility and dissolution rate enhancement as well as the potential cytotoxic activity of raloxifene-loaded nanosponges formulation.
The fabrication and optimization of cyclodextrin nanosponges crosslinked with diphenyl carbonate was portrayed through stoichiometric selection of cyclodextrin-to-crosslinker ratio. The complexation phenomenon and nanosponges formation were validated using FTIR, PXRD, TEM, and SEM examination.
Raloxifene-loaded nanosponges exhibited a 440±8.5 nm particle size, a negative zeta potential of 25.18±2.3 mV and a partial drug incorporation. Moreover, the drug loaded nanosponges demonstrated an in-vitro significantly enhanced dissolution behavior. Furthermore, the in-vitro cytotoxicity of the raloxifene-loaded nanosponges on MCF-7 breast cancer cell lines was statistically significant compared to the complex-free raloxifene.
The cytotoxic behavior provided evidence that the incorporation of raloxifene within the nanosponges structure enhanced its anticancer activity and represents a potential nanocarrier for anticancer agent delivery.
世界卫生组织(WHO)的数据显示,癌症是第二大常见死因,每六例死亡中就有一例与癌症有关。乳腺癌在女性中发病率最高,是最常见的肿瘤。雷洛昔芬是一种选择性雌激素受体调节剂,已被用作绝经后妇女乳腺癌的化疗药物。然而,其较差的水溶性限制了其临床应用。β-环糊精基纳米载体是一类新型纳米载体,用于提高难溶性药物的溶解度和溶解速率。
本研究旨在探讨载雷洛昔芬纳米海绵制剂的增溶和溶解速率增强以及潜在的细胞毒性活性。
通过选择环糊精与交联剂的化学计量比来描绘二苯基碳酸酯交联的环糊精纳米海绵的制备和优化。使用傅里叶变换红外光谱(FTIR)、粉末 X 射线衍射(PXRD)、透射电子显微镜(TEM)和扫描电子显微镜(SEM)检查来验证络合现象和纳米海绵的形成。
载雷洛昔芬纳米海绵的粒径为 440±8.5nm,zeta 电位为-25.18±2.3mV,部分药物包封。此外,载药纳米海绵表现出显著增强的体外溶解行为。此外,与游离雷洛昔芬相比,载雷洛昔芬纳米海绵对 MCF-7 乳腺癌细胞系的体外细胞毒性具有统计学意义。
细胞毒性行为表明,雷洛昔芬在纳米海绵结构中的包封增强了其抗癌活性,代表了一种用于抗癌药物传递的潜在纳米载体。